Three things to know:
1. Committee Chairman Rep. Frank Pallone, D-N.J., and top-ranking member Rep. Diana DeGette, D-Colo., requested information from Sanofi, Eli Lilly and Novo Nordisk on the average price of their insulin products and annual net profits.
“Despite the fact that it has been available for decades, prices for insulin have skyrocketed in recent years, putting it out of reach for many patients,” the lawmakers wrote in the letters. “As one of the few manufacturers of insulin in the United States, your company is well-suited to shed light on these issues and offer potential solutions.”
2. The drugmakers must provide all requested information by Feb. 13. If they do not respond, the committee has the power to subpoena drugmakers to testify at a hearing, a spokeswoman for Ms. DeGette told Reuters.
3. Sanofi told the publication it plans to work with the committee to fulfill its request for information. Novo Nordisk and Eli Lilly did not immediately respond to Reuters‘ requests for comment.
More articles on pharmacy:
Prescription drug price transparency and its visible impact on medication adherence
Key thoughts on controlling pharmacy spend for hospitals
CVS, Walgreens piloting dental services: 3 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
